StockData

MDxHealth vs Veracyte

MDXH and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MDXH and VCYT compare

MDxHealth grew revenue faster over the last twelve months (19.8% versus 17.3% for Veracyte).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −31.1% at MDxHealth.

Veracyte scores higher on the StockData Score (16 against 5 for MDxHealth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMDXHVCYT
Size and price
Market cap–$1.9B
Share price$0.149$24.23
Change, 1 year−95.9%−38.4%
Change, 5 years−98.4%−41.7%
Beta (5Y)3.131.92
Employees364755
StockData Score
Total score516 (better)
Valuation score04 (better)
Growth score33
Performance score13 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–17.3×
P/S–3.5×
P/B–1.4×
EV/EBITDA–13.0×
P/FCF–11.7×
FCF yield–8.5%
Fair value–$36.51
Margin of safety–33.6%
Growth
Revenue growth (TTM)19.8% (better)17.3%
Revenue growth, 5Y average42.3% (better)34.5%
Net income growth (TTM)–335%
EPS growth (TTM)–324%
Profitability
Gross margin64.5%71.7% (better)
Operating margin−13.4%18.8% (better)
Net margin−31.1%20.4% (better)
FCF margin−3.1%29.5% (better)
Return on equity–8.8%
Return on invested capital–10.0%
Financial health
Debt / equity–0.00
Interest coverage−0.6×–
Current ratio1.089.16 (better)
Altman Z-score–12.65
Piotroski F-score37 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions32.3%111%
Held by insiders–1.7%
Insider net buying, 12 months$991K (better)−$18.6M
Short interest, % of float–12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.